This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Drug Names(s): CG200745
Description: CG200745 is an anti-cancer agent that deactivates HDAC, an enzyme that catalyzes histone deacetylation.
CG200745 is being developed to potentially overcome negative side effect profiles of traditional cancer therapies. One of the major flaws of traditional oncology agents is the severe toxicity issue as current agents tend to target and kill even the normal healthy cells that are around the cancerous cells. Because CG200745 has been designed to specifically target the cancerous cells, it is also referred to as a “Molecular Targeted Cancer Therapeutic” that will not harm the non-cancerous cells.
Additional information available to subscribers only: